Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.

The scientific community said goodbye to a number of leading researchers this year.

In human cells, researchers deploy the genome editor to snip out toxic repetitive sequences.

Researchers identify a new ALS-associated gene thanks to funds generated by the social media challenge that went viral in summer 2014.

At first blush, do-it-yourself clinical trials seem pointless and reckless. But a deeper truth pervades the research and the patients who drive it forward.

Harvard Professor Marc Weisskopf discusses the potential link between formaldehyde and ALS.

Data on the links between ALS and the chemical have been contradictory, but the latest study suggests undertakers are at risk.

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

Statisticians who normally crunch numbers to forecast trends in the food-service industry turn their attention to bettering treatment of ALS.